Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 10/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 7/20 | 0.38 |
| ▸ | RPS6KA2 | Q15349 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19795265 | 0.84 | GRM4 (0.60) | GRM4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19801933 | 0.82 | GRM4 (0.40) | GRM4CYP1A2 | |
| SCHEMBL19795101 | 0.81 | GRM4 (0.41) | GRM4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19801973 | 0.76 | GRM4 (0.34) | GRM4CYP1A2 | |
| SCHEMBL14819959 | 0.72 | ADORA3 (0.43) | CYP1A2RPS6KA3RPS6KA2ABCB1ABCG2 | |
| SCHEMBL19801705 | 0.71 | GRM4 (0.73) | GRM4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19801676 | 0.70 | GRM4 (0.50) | GRM4CYP1A2 | |
| SCHEMBL14805682 | 0.69 | ADORA3 (0.40) | RPS6KA3RPS6KA2ABCB1ABCG2 | |
| SCHEMBL18193674 | 0.69 | ADORA3 (0.43) | RPS6KA3RPS6KA2 | |
| SCHEMBL19795264 | 0.69 | GRM4 (0.72) | GRM4CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022746-A1 | INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
| US-20180022746-A1 | INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022746-A1 | INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRIK4, GRM4, GRIA4 | GRM4 2/4885CYP1A2 2619/4885RPS6KA3 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.